Project description
A novel targeted anti-cancer therapy
Harnessing the power of the immune system to fight cancer is an attractive therapeutic approach. More specifically, conjugating chemotherapeutic drugs to tumour-specific antibodies improves drug delivery and efficiency while minimising side effects. The EU-funded PAC Synthesis project proposes to combine the advantages of protein degradation and antibody targeting into a new therapeutic platform. Scientists will generate conjugates between proteolysis targeting chimeras (PROTAC) and antibodies targeting the myeloid CD33 protein present in acute myeloid leukaemia cells. The employed chemistry ensures conjugate stability in the blood and efficient release of the PROTAC once internalised by cancer cells.
Fields of science
Programme(s)
Funding Scheme
MSCA-IF-EF-ST - Standard EF
Coordinator
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Net EU contribution
€ 212 933,76
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
United Kingdom
CB2 1TN Cambridge
United Kingdom
See on map
Region
East of England East Anglia Cambridgeshire CC
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00